Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025

Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI

Read more at globenewswire.com